On 26 August 2005, orphan designation (EU/3/05/303) was granted by the European Commission to Cellerix S.L., Spain, for human autologous mesenchymal adult stem cells extracted from adipose tissue for the treatment of anal fistula.
The sponsor changed name to Cellerix S.A. in September 2008 and then to TiGenix S.A.U. in February 2013.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
Human autologous mesenchymal adult stem cells extracted from adipose tissue
|Disease / condition||
Treatment of anal fistula
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.